expanded further by ALCOA+ to include complete, consistent, enduring, and available data standards.

Regulatory Emphasis on Data Integrity

Global regulators stress that any compromise in data integrity can undermine trial results and risk patient safety. Guidelines from CDSCO and SAHPRA reinforce ICH E6’s position that clinical data must be trustworthy, retrievable, and auditable.

Key ICH E6(R2)/(R3) Provisions Related to Data Integrity:

1. Quality Management Systems (QMS): Sponsors must implement a risk-based QMS to prevent and detect data errors early.
2. Trial Master File (TMF) Maintenance: TMFs must be accurate, complete, and organized to enable timely access for inspections.
3. Monitoring and Source Data Verification (SDV): Emphasis on risk-based monitoring to ensure data accuracy without overburdening sites.
4. Electronic Systems: Validation of electronic systems and audit trails is required for electronic records and signatures.
5. Investigator Oversight: The PI remains responsible for the integrity of all data generated at the site, even if tasks are delegated.

Checklist for Data Integrity Compliance

1. Data Collection and Recording

• Ensure all data entries are traceable and timestamped.
• Use validated Electronic Data Capture (EDC) systems with role-based access controls.
• Prohibit uncontrolled spreadsheets or informal note-keeping.

2. Audit Trails and Change Control

• Maintain audit trails for all critical data points.
• Any changes must be documented with reasons and timestamps.

3. Investigator Site Practices

• Follow GMP documentation and GCP-aligned SOPs for data entry and correction.
• Train staff in ALCOA+ principles and their practical application.

4. Monitoring and QA Oversight

• Use risk-based monitoring approaches to focus on high-impact data.
• Perform data review and reconciliation throughout the study lifecycle.

Common Data Integrity Pitfalls in Clinical Trials

• Backdating or pre-entering data to match expected timelines
• Unlogged changes or data overwrites without justification
• Use of paper notes not transcribed into official records
• Missing source documentation for key endpoints
• Inadequate training on handling protocol deviations

These issues often emerge during inspections and lead to findings, delaying approvals or leading to trial rejection.

ICH E6 Data Integrity in the Age of Digital Trials

With the advent of decentralized trials and remote data collection, ICH E6 compliance now involves advanced tools:

• Validated eConsent systems with audit trails
• eSource data from wearables and apps integrated with trial databases
• Remote monitoring platforms for real-time data access
• Document version control and backup policies

Such technologies also demand robust training, especially when conducting Stability Studies with automated instruments where data feeds must be secured and validated.

Best Practices to Strengthen Data Integrity

1. Implement SOPs covering every step of data handling and documentation.
2. Use digital signatures and secure access controls.
3. Perform periodic data audits and log reviews.
4. Establish a deviation handling and CAPA system aligned with Pharma SOP documentation.
5. Train teams using real-world examples and protocol simulations.

Conclusion

Data integrity is not just a technical concern—it reflects the ethical and scientific foundation of clinical research. The ICH E6 guidelines set the benchmark for protecting data quality in a rapidly evolving clinical environment. By embracing ALCOA+ principles, leveraging digital systems, and maintaining rigorous oversight, sponsors and sites can ensure data that is inspection-ready and globally acceptable. Aligning your practices with ICH E6 ensures that participant rights are safeguarded and that trial outcomes remain credible across borders.